Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II ...

CML Treatment Goals Are Evolving: Why Deeper Responses and Quality of Life Matter More Than Ever

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...
Pharmabiz

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...
PharmiWeb

Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US

Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through ...
finanzen.at

Press Release: Novartis Scemblix(R) receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, ...

Novartis Pharma AG: Novartis Scemblix receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix i ...